Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T4221 |
PF-06260933
PF-6260933,PF 6260933,PF6260933 |
MAPK | MAPK |
PF-06260933 是一种具有高度选择性及口服有活性的MAP4K4小分子抑制剂,在激酶实验中IC50为 3.7 nM,在细胞实验中IC50为 160 nM。 | |||
T33945 |
PF-06260933 HCl
PF06260933 dihydrochloride,PF-06260933 dihydrochloride,PF 06260933 dihydrochloride |
||
PF-06260933 Dihydrochloride is a MAP4K4 (HGK) inhibitor (IC50 = 140 nM). It can improve the fasting hyperglycemia in mice. In addition, it inhibited Mink and Tnik (IC50 values of 8 and 13 nM, respectively). | |||
T36016 | PF 06260933 dihydrochloride | ||
MAP4K4 (HGK) inhibitor (IC50 = 140 nM). Also inhibits MINK and TNIK (IC50 values are 8 and 13 nM, respectively). Improves fasting hyperglycemia in mice. Orally active. Ammirati et al (2015) Discovery of an in vivo tool to establish proof-of-concept for MAP4K4-based antidiabetic treatment. ACS Med.Chem.Lett. 6 1128 PMID:26617966 |